In Vivo Evolution of Carbapenem Resistance in Hypervirulent Klebsiella Pneumoniae in a Patient Undergoing Long-Term Treatment

Na Tang,Jinshu Hu,Yingying Zhao,Yuqin Song,Chao Wang,Gang Zhang,Dawei Wei,Hailing Fang,Chao Li,Rufu Jia,Jie Feng
DOI: https://doi.org/10.1093/jac/dkab380
2022-01-01
Journal of Antimicrobial Chemotherapy
Abstract:Hypervirulent Klebsiella pneumoniae (hvKP) can cause invasive infections, even outside of hospital settings.1 The hvKP strains are characterized by special virulence factors, including regulator-increased capsule expression and two siderophores that enhance iron uptake.2 Most hvKP strains are susceptible to commonly used antimicrobial agents.3 However, clinicians have recently faced the emergence and dissemination of carbapenem-resistant hvKP (CR-hvKP), which causes severe infections that are extremely difficult to treat, resulting in high mortality rates.4–6 Therefore, an increased understanding of the evolutionary trajectory of CR-hvKP, especially of the genetic alterations that occur in patients undergoing long-term antibiotic treatment, is essential to provide a basis to control the spread of these strains throughout populations and healthcare networks. In this study, we found that the hvKP clone ST218 developed carbapenem resistance in a single patient over time by acquiring the blaKPC plasmid. The MDR K. pneumoniae clone ST585 acted as the donor of the blaKPC plasmid. This study was approved by the Research Ethics Committee of the Institute of Microbiology, Chinese Academy of Sciences (Permit Number: SQIMCAS2019080).
What problem does this paper attempt to address?